Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

MRUS Relative to the S&P 500

MRUS Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Merus BV (NASD:MRUS) seasonal charts above shows that a Buy Date of December 6 and a Sell Date of March 10 has resulted in a geometric average return of 31.86% above the benchmark rate of the S&P 500 Total Return Index over the past 9 years. This seasonal timeframe has shown positive results compared to the benchmark in 9 of those periods. This is an excellent rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 9 years by an average of 29.61% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 9 years of data is available for shares of MRUS, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

To download MRUS seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: MRUS